ARNA Arena Pharmaceuticals, Inc. (MM) Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management
Arena reports increased sequential sales for Belviq in Q1 2015
In Q1 2015, Arena reported USD 12.8 million in net product sales by partner Eisai. Net product sales in South Korea during first quarter of 2015 were USD 2.2 million. An Eisai internal sales force (n=90) will promote Belviq and two other Eisai products. A shared contract sales force (n=230) will promote Belviq together with another product from another pharmaceutical company.
...aus meiner Sicht ganz heißes Eisen im Aquisitionspoker von Big Pharma mit überragender Pipeline. Aktuelle Meldungen (s. News) untermauern den Fortschritt!